Trial Information

A Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Elderly Patients With Metastatic Colorectal Cancer

Colorectal cancer is primarily a disease of the elderly, with the median age in the United
States of 70 years. Age greater than 65 years at presentation is not a contraindication to
standard therapies; acceptable morbidity and mortality, as well as long term survival, are
achieved in this patient population. However, studies evaluating combination therapy have
generally involved younger patients with high performance status scores. Given the
non-over-lapping safety profiles of the proposed study agents and the potential synergy, it
would be of benefit to explore the combination of oxaliplatin, capecitabine, and bevacizumab
in the treatment of older patients with colorectal cancer. Time to progression, overall
response, duration of response, and toxicity profile will be evaluated. The feasibility of
using a self-report geriatric assessment tool will also be assessed.